TIGIT and ovarian carcinoma: Xu et al. [108] found that the immune coinhibitory receptor TIGIT was highly expressed on exhausted cytotoxic CD8+ T cells (CD8+ TEX) and that TIGIT blockade could significantly reduce ovarian cancer tumor growth in mouse models.